Company introduction

Beijing Sinogenetic Biotechnology Co., Ltd. was established in 2021. Relying on the parent company's animal cloning and gene editing technology platform, the company has developed and constructed multi-species (dog/pig/cat/rabbit/mouse/rat) gene editing animal models, set up drug analysis and evaluation platforms such as pharmacological efficacy, pharmaco toxicology and safety evaluation, and established multi-omics analysis, imaging electrophysiology and behavioral analysis platforms. For , It provides full-process services of preclinical CRO based on multi-breed gene editing model animal development and application for drug development and device evaluation, especially for innovative drug development such as gene therapy and cell therapy.

oint laboratory of domestic dogs
Postdoctoral Program
Large animal model innovation platform
National high-tech enterprises

Model animal

Beijing Sinogenetic Biotechnology Co., Ltd. was established in 2021.?Relying on the parent company's animal cloning and gene editing technology platform, the company has developed and constructed multi-species (dog/pig/cat/rabbit/mouse/rat) gene editing animal models, set up drug analysis and evaluation platforms such as pharmacological efficacy, pharmaco toxicology and safety evaluation platforms,?and established multi-omics analysis, imaging electrophysiology and behavioral analysis platforms.?It provides full-process preclinical CRO services on multi-breed gene editing model animal development and application for drug development and device evaluation, especially for innovative drug development such as gene therapy and cell therapy.?

The ApoE gene editing dog| systemic atherosclerosis model?

?Scn5a gene editing dogs | model of sudden cardiac death

Rpe65 gene editing dog | congenital amaurosis model

Gck gene editing dogs | neonatal diabetes model

Shank3 gene editing dog | autism spectrum disorders model